Skip to main content

Table 1 Baseline demographics and clinical characteristics among participants of the BETAEVAL study (N = 143)

From: Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study

Characteristic  
Age, years
 Mean (SD) 41.2 (11.5)
 Median (range) 40 (21–79)
Gender, n (%)
 Women 99 (69.2)
 Men 44 (30.8)
BMI, kg/m2
 Mean (SD) 25.8 (5.2)
 Median (range) 24.5 (17.6–47.8)
Diagnosis, n (%)  
 RRMS 136 (95.1)
 CIS 7 (4.9)
Time between first symptoms and initial diagnosis, months; (N = 87)
 Mean (SD) 15.2 (29.4)
 Median (range) 1.32 (0–137.3)
Duration of disease, months; (N = 105)
 Mean (SD) 57.5 (73.0)
 Median (range) 29.9 (0.0–372.6)
EDSS, median (range); (N = 124) 2.0 (0–6.5)
Previous treatment, n (%)
 Betaferon® 106 (74.1)
 Other treatment 6 (4.2)
 No previous treatment 31 (21.7)
Previous usage of auto-injector for Betaferon® treatment among patients who received Betaferon® previously (N = 106), n (%)
 Any 84 (79.3)
  BETACOMFORT® 51 (60.7)
  BETAJECT Comfort® 20 (23.8)
  BETAJECT lite® 3 (3.6)
  Other 10 (11.9)
Participation in BETAPLUS® nurse support programme, n (%) 87 (60.8)
Employment status, n (%)
 Employed 107 (74.8)
 Retired 13 (9.1)
 Keeping house 7 (4.9)
 Student 3 (2.1)
 Seeking work 3 (2.1)
 Self-employed 2 (1.4)
 Other 3 (2.1)
  1. Numbers (%) may not add up to total numbers (100%) due to missing values
  2. SD standard deviation, BMI body mass index, RRMS relapsing remitting multiple sclerosis, CIS clinically isolated syndrome, EDSS expanded disability status scale